Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
40%
Ph early_phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

completed480%
not_yet_recruiting120%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingearly_phase_1

Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.

NCT07429071
completednot_applicable

Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.

NCT04199078
completed

Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).

NCT06399341
completed

Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.

NCT04199260
completednot_applicable

Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV

NCT04002154

Clinical Trials (5)

Showing 5 of 5 trials
NCT07429071Early Phase 1

Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.

Not Yet Recruiting
NCT04199078Not Applicable

Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.

Completed
NCT06399341

Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).

Completed
NCT04199260

Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.

Completed
NCT04002154Not Applicable

Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV

Completed

All 5 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
5